New hope for hard-to-treat prostate cancer: drug-radiation combo enters trial

NCT ID NCT07451795

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated Jun 04, 2026 · Updated 13 times

Summary

This study tests whether adding a new drug (SHR-1701) to targeted radiation (SBRT) can slow the growth of advanced prostate cancer that no longer responds to hormone therapy. About 66 men with metastatic castration-resistant prostate cancer will be enrolled. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Fudan University Shanghai Cancer Center Xiamen Branch
RECRUITING

Xiamen, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Fujian Cancer Hospital
RECRUITING

Fujian, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) PROSTATE CANCER